Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared a post on LinkedIn:
“Since the first phase 1 trial of T-DXd, it was clear that this drug would end up being transformative when taken to the curative setting.
Today, the FDA approved T-DXd for the neoadjuvant or adjuvant treatment of HER2 positive early-stage breast cancer, marking a major advancement in the field.”
Other articles featuring Dr. Tarantino on OncoDaily.